When considering combination therapy for prostate cancer, it is crucial to consider amplifying antigen-specific CD8+ T cells, efficiently trafficking them by TIME reprogramming, and reinvigorating and sustaining their survival via ICB and cytokines. Here, CD8A is linked to Familial prostate cancer.